Web Results

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. SUN ...

search.rpxcorp.com/lit/njdce-331329-boehringer-ingelheim-pharmaceuticals-v-sun-pharmaceutical-industries

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. SUN PHARMACEUTICAL INDUSTRIES LTD et al. 3:16-cv-01727; Filed: 03/29/2016; Closed: ...

TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

www.leagle.com/decision/1995235234Conn1_1235/TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

234 Conn. 1 (1995). ANUSHAVAN G. TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. Supreme Court of Connecticut. Argued March 21 ...

Initial Transfer Order - District of Connecticut

ctd.uscourts.gov/sites/default/files/forms/2516IO.pdf

Apr 3, 2014 ... KG, ET AL., C.A. No. 3:13-01776. Eastern District of Pennsylvania. MIAMI-LUKEN , INC. V. BOEHRINGER INGELHEIM PHARMA GMBH & CO.

A Randomized, Controlled, Pilot Study of Acamprosate Added to ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3794470/

Comparisons between treatment arms (acamprosate vs placebo) were made by the .... Tiihonen et al found similar benefit in 62 alcoholic patients. ... served in advisory/consultative relationships with Boehringer Ingelheim and Pfizer. ... Inc, Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, Wyeth-Ayerst Laboratories.

Effectiveness and safety of different azacitidine dosage regimens in ...

www.sciencedirect.com/science/article/pii/S0145212614000666

AZA 5-2-2, p = 0.0021; AZA 5 vs. AZA 7, p ... Table 3. Assigned scores in lower- risk patients based on the prognostic score described by Garcia-Manero et al.

Reduced risk of hypoglycemia with once-daily glargine versus twice ...

www.sciencedirect.com/science/article/pii/S1056872714001184

... benefit of this analogue in reducing the risk of hypoglycemia (Bazzano et al., 2008). .... period was higher with NPH, compared with glargine (15,527 vs 11,995 ). ..... al., 2001; J. Rosenstock, S.L. Schwartz, C.M. Clark Jr., G.D. Park, D.W. Donley, ... Johnson, Novartis and Boehringer Ingelheim, and Amylin Pharmaceuticals.

Full Text - Learning & Memory - Cshlp.org

learnmem.cshlp.org/content/20/12/730.full

As part of the “extended amygdala” (Alheid and Heimer 1988; Alheid et al. .... ANOVA indicated a significant effect of Stress Level (i.e., before vs. after shock), F (1 .... meloxicam (Metacam, Boehringer Ingelheim) to reduce post-operative discomfort. ... was facilitated with 0.5 mg/kg atipamezole HCl (Antisedan, Orion Pharma).

CGRP antagonist infused into the bed nucleus of the stria terminalis ...

learnmem.cshlp.org/content/20/12/730.full.pdf

et al. 2009), intra-BNST infusions of calcitonin gene-related pep- tide (CGRP) ... 2004; Donley et al. .... significant effect of Stress Level (i.e., before vs. after shock) ,. F(1,14) ..... dexmedetomidine HCl (Dexdomitor, Orion Pharma), and received ... Boehringer Ingelheim) to reduce post-operative discomfort. .... Glassbeads Inc.).

More Info

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC ...

search.rpxcorp.com

BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v. HEC PHARM CO. , LTD. et al. 3:15-cv-05982; Filed: 08/04/2015; Case Updated Daily; Latest ...

Boehringer Ingelheim Pharmaceuticals, Inc. | Federal Trade ...

www.ftc.gov

Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir. ), Response of FTC to Petition for Rehearing En Banc (113.12 ...

Differential Effects of Teriparatide and Denosumab on Intact PTH ...

www.ncbi.nlm.nih.gov

Feb 10, 2016 ... Medical writing support was provided by Lori Kornberg (INC Research ... and is a consultant for Merck, Tarsa Pharmaceuticals, and Radius Health. ... from Amgen, Boehringer Ingelheim, Immunodiagnostics, Lilly, Merck, ... Cummings SR, San Martin J, McClung MR, et al. .... Ma YL, Zeng Q, Donley DW, et al.